Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 24 04:00PM ET
5.41
Dollar change
+0.64
Percentage change
13.42
%
Index- P/E- EPS (ttm)- Insider Own36.52% Shs Outstand22.24M Perf Week-17.53%
Market Cap120.37M Forward P/E- EPS next Y-4.59 Insider Trans12.65% Shs Float14.13M Perf Month-50.91%
Income- PEG- EPS next Q-0.80 Inst Own53.73% Short Float8.10% Perf Quarter-
Sales- P/S- EPS this Y90.18% Inst Trans- Short Ratio6.85 Perf Half Y-
Book/sh-111.82 P/B- EPS next Y-15.16% ROA- Short Interest1.14M Perf Year-
Cash/sh4.71 P/C1.15 EPS next 5Y- ROE- 52W Range4.77 - 15.24 Perf YTD-62.04%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-64.50% Beta-
Dividend TTM- Quick Ratio10.54 Sales past 5Y0.00% Gross Margin- 52W Low13.42% ATR (14)1.06
Dividend Ex-Date- Current Ratio10.54 EPS Y/Y TTM- Oper. Margin- RSI (14)29.10 Volatility15.97% 14.34%
Employees72 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price23.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-2207.48% Payout- Rel Volume0.77 Prev Close4.77
Sales Surprise- EPS Surprise-1817.19% Sales Q/Q- EarningsMay 13 BMO Avg Volume167.26K Price5.41
SMA20-35.03% SMA50-43.25% SMA200-46.27% Trades Volume128,075 Change13.42%
Date Action Analyst Rating Change Price Target Change
Apr-22-24Initiated Piper Sandler Overweight $20
Apr-22-24Initiated Leerink Partners Outperform $25
Apr-22-24Initiated Guggenheim Buy $24
Boundless Bio, Inc. is a clinical-stage oncology company, which is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA. The company was founded by Vineet Bafna, Paul Mischel, Benjamin F. Cravatt, and Jonathan E. Lim on April 10, 2018 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RA CAPITAL MANAGEMENT, L.P.10% OwnerApr 02 '24Buy16.00312,5005,000,0001,884,787Apr 04 04:15 PM
ARCH Venture Fund IX, L.P.10% OwnerApr 02 '24Buy16.00200,0003,200,0001,181,766Apr 04 04:30 PM
CRANDELL KEITH10% OwnerApr 02 '24Buy16.00200,0003,200,0001,181,766Apr 04 04:30 PM
Burow KristinaDirectorApr 02 '24Buy16.00200,0003,200,0001,181,766Apr 04 04:30 PM